Vividhmargi Investments Private Limited (VIPL), a promoter group entity, has created an indirect encumbrance over Gujarat Themis Biosyn Limited shares through a pledge and non-disposal undertaking on its stake in Pharmaceutical Business Group (India) Limited (PBGIL). The disclosure, filed under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, reveals that VIPL has pledged 25,24,245 equity shares in PBGIL, constituting 51% of its issued and paid-up share capital. Since PBGIL holds 47.02% of Gujarat Themis Biosyn, this move creates a significant indirect lien on the listed company’s promoter holdings.

The encumbrance was created in favor of CTL Trusteeship Limited, acting as the debenture trustee for OSS Software Solutions Labs Private Limited. A Pledge Agreement cum Non-Disposal Undertaking dated June 28, 2026, formalized the security interest, with the pledge taking effect from June 29, 2026. Additionally, VIPL provided a non-disposal undertaking over another 21,57,855 equity shares in PBGIL, representing 47.988% of its capital. This structure ensures that nearly the entire stake held by VIPL in PBGIL is now subject to restrictions or security interests.

Structure of Indirect Encumbrance

The chain of ownership linking the pledge to Gujarat Themis Biosyn is direct. VIPL holds 49,49,500 equity shares in PBGIL, which constitutes 98.988% of PBGIL’s issued and paid-up share capital. PBGIL, in turn, holds 5,12,40,000 equity shares in Gujarat Themis Biosyn, accounting for 47.02% of the listed company’s total diluted share and voting capital. Consequently, the pledge over VIPL’s majority stake in PBGIL translates into an indirect encumbrance on the substantial block held by PBGIL in the listed entity.

The disclosure was submitted to BSE Limited and National Stock Exchange of India Limited on July 1, 2026, by Deesha Srikkanth, Senior Vice President at CTL Trusteeship Limited. The filing clarifies that no direct acquisition of shares in Gujarat Themis Biosyn has occurred; rather, the regulatory requirement stems from the creation of encumbrances over the intermediate holding company. The total equity share capital of Gujarat Themis Biosyn remains unchanged at INR 10,89,65,265, comprising 10,89,65,265 fully paid-up equity shares of INR 1/- each.

What the Numbers Show

The pledge covers exactly 51% of PBGIL’s share capital, while the non-disposal undertaking covers the remaining 47.988%, leaving only a negligible fraction of VIPL’s stake in PBGIL unencumbered. This near-total restriction on VIPL’s ability to dispose of its PBGIL shares suggests that the financing arrangement secured by OSS Software Solutions Labs Private Limited is heavily collateralized against the promoter group’s strategic holding. For investors in Gujarat Themis Biosyn, this indicates that the promoter group’s liquidity needs are being met by leveraging their control stake in the listed company, albeit indirectly.

Gujarat Themis Biosyn has initiated a postal ballot to seek shareholder approval for raising up to ₹1,000 crore through a Qualified Institutions Placement (QIP), alongside authorizing debt issuance up to ₹1,500 crore. The move aims to fund growth opportunities, repay existing borrowings, and optimize the balance sheet. Remote e-voting, managed by Central Depository Services (India) Limited (CDSL), commenced on July 24, 2026, at 9:00 a.m. (IST) and concludes on August 22, 2026, at 5:00 p.m. (IST). Shareholders holding equity as of the July 10, 2026 cut-off date are eligible to vote.

The proposal supersedes a previous resolution passed on July 8, 2026, granting the Board broader discretion over equity issuance. Under the new terms, no single allottee can receive more than 50% of the issue size, and at least 10% of securities must be allotted to mutual funds. Issued securities will carry a one-year lock-in period from the date of allotment. The Board is authorized to offer a discount of up to 5% on the floor price determined under the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

The second special resolution seeks approval for the private placement of non-convertible debentures (NCDs) and other debt securities, with an outstanding principal amount not exceeding ₹1,500 crore. This authorization allows the Board to diversify the company’s debt portfolio and access competitive borrowing sources. The Board retains authority to determine terms, pricing, interest rates, and security structures based on prevailing market conditions. These debt securities may be listed on recognized stock exchanges as per statutory provisions.

The third resolution proposes an amendment to Article 13(1)(c) of the Articles of Association. Currently, the Articles require that the price of further share issues be determined by a registered valuer who submits a valuation report. The proposed amendment removes this unconditional requirement, aligning internal governance documents with the Companies Act, 2013 and SEBI regulations. This change ensures valuation reports are obtained only when explicitly mandated by law.

Proceeds from the QIP will be utilized for prepayment of existing borrowings, investments in subsidiaries, capital expenditure, working capital, and inorganic growth through acquisitions. Not more than 25% of net proceeds can be used for general corporate purposes. A monitoring agency registered with SEBI will track utilization if the issue size exceeds ₹100 crore, submitting quarterly reports until full deployment. The Board confirmed no directors, promoters, or key managerial personnel intend to subscribe to the QIP, ensuring no change in control or management.

What the Numbers Show

The dual-track fundraising strategy—combining a ₹1,000 crore equity mandate with a ₹1,500 crore debt facility—signals a significant push for balance sheet optimization. By securing upfront shareholder approval for both instruments, Gujarat Themis Biosyn positions itself to act swiftly on market opportunities without seeking repeated approvals. The restriction limiting general corporate purpose usage to 25% of QIP proceeds indicates a focused deployment strategy, prioritizing debt reduction and specific growth initiatives over unrestricted cash accumulation.